Everything below concerns Immunomodulatory peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Food chains are often used in ecological modeling (such as a three-species food chain). They are simplified abstractions of real food webs, but complex in their dynamics and mathematical implications. In its simplest form, the length of a chain is the number of links between a trophic consumer and the base of the web. The mean chain length of an entire web is the arithmetic average of the lengths of all chains in the food web. The food chain is an energy source diagram. The food chain begins with a producer, which is eaten by a primary consumer. The primary consumer may be eaten by a secondary consumer, which in turn may be consumed by a tertiary consumer. The tertiary consumers may sometimes become prey to the top predators known as the quaternary consumers. For example, a food chain might start with a green plant as the producer, which is eaten by a snail, the primary consumer. The snail might then be the prey of a secondary consumer such as a frog, which itself may be eaten by a tertiary consumer such as a snake which in turn may be consumed by an eagle. This simple view of a food chain with fixed trophic levels within a species: species A is eaten by species B, B is eaten by C, ... is often contrasted by the real situation in which the juveniles of a species belong to a lower trophic level than the adults, a situation more often seen in aquatic and amphibious environments, e.g., in insects and fishes. This complexity was denominated metaphoetesis by G. E. Hutchinson, 1959.
== AZF1 / AZFa == The AZF1 (Azoospermia Factor 1) gene is likely located in the euchromatic part of the long arm in Yq11.23. AZF1 is 792kb long and just distal to the centromere of the Y chromosome. AZF1 genes are involved in spermatogenesis in the testes. Common phenotypic manifestations of deletions in this region are azoospermia and Sertoli cell-only syndrome. Men with a complete deletion in the AZFa region are unable to produce testicular spermatozoa for ICSI. There are several candidate genes in the AZFa region that have been shown to cause infertility in males: Ubiquitin Specific Peptidase 9, Y-Linked (USP9Y), DEAD Box RNA helices, Box3, Y-linked (DBY), Ubiquitously Transcribed Tetratricopeptide Repeat Containing, Y-linked (UTY), and Thymosin Beta 4, Y-Linked (TB4Y).
== See also == Mepolizumab, anti–IL-5 to treat chronic rhinosinusitis with nasal polyps Omalizumab, anti–immunoglobulin E to treat chronic rhinosinusitis with nasal polyps Tezepelumab, anti-thymic stromal lymphopoietin to treat chronic rhinosinusitis with nasal polyps
The traditional Maine Italian sandwich is prepared using a long, soft bread roll or bun with ham and bologna along with American cheese, tomato, onion, green bell pepper, Greek olives, pickles, olive oil or salad oil, salt and cracked black pepper. Additional ingredients, such as pepperoni, banana pepper, or lettuce may be added to the sandwich. The sandwich is often cut in half to make it easier to handle.
Garlic cloves are peeled and sliced. In most cases, the garlic is then heated to a temperature of between 150 and 160 °C (302 and 320 °F). The water is removed to a moisture content of about 6.5%. The dehydrated garlic is then further sliced, chopped, or minced until the powder is reduced to the desired particle size. Manufacturing garlic powder on a larger scale involves various steps, from extraction of the garlic bulbs to packaging the final powder. After harvesting the raw garlic, bulbs are cleaned under mild pressure to remove skin and separate the cloves. The garlic is then dehydrated using both historical and newly developed methods. While old methods, such as using natural elements of sun and wind to evaporate water from foodstuffs are still utilized in many parts of the world, new technology has enabled for more flexible and economically viable procedures, such as vacuum and freeze drying. Once the garlic cloves are dried and dehydrated, they are powdered using large scale machines and powdering units. Milling is the process of using mechanical action to break down substances through rotary cutting. As powder processing generally includes additives and is done in a bulk scale, the milling process breaks down materials to the required size for suppliers. Milling may require a series of steps, from de-agglomeration to fine grinding. The four components include delumpers, conical mills, hammermills and fine grinders.
Sources: en.wikipedia.org
As a passenger during a long car drive, when insulin needs are different due to inactivity. While driving on an extended trip, to reduce the risk of hypoglycemia, a lower temporary basal rate may be programmed. During and after spontaneous exercise or sports activities, when the body needs less insulin. During illness or stress, when basal demand increases due to insulin resistance. When blood ketones are present, when additional insulin is needed. When on an extended fast (such as Ramadan, Lent, or Yom Kippur) when basal requirements may be lower. During menses, when additional basal insulin might be needed.
Estradiol is known to correlate with aggression in male mice. Moreover, the conversion of testosterone to estradiol regulates male aggression in sparrows during breeding season. Rats who were given anabolic steroids that increase testosterone were also more physically aggressive to provocation as a result of "threat sensitivity". The relationship between testosterone and aggression may also function indirectly, as it has been proposed that testosterone does not amplify tendencies towards aggression, but rather amplifies whatever tendencies will allow an individual to maintain social status when challenged. In most animals, aggression is the means of maintaining social status. However, humans have multiple ways of obtaining status. This diversity could explain why some studies find a link between testosterone and pro-social behavior, if pro-social behavior is rewarded with social status. Thus the link between testosterone and aggression and violence is due to these being rewarded with social status. The relationship may also be one of a "permissive effect" whereby testosterone does elevate aggression levels, but only in the sense of allowing average aggression levels to be maintained; chemically or physically castrating the individual will reduce aggression levels (though not eliminate them) but the individual only needs a small-level of pre-castration testosterone to have aggression levels to return to normal, which they will remain at even if additional testosterone is added.
Trump formally notified the United States Congress on 1 October 2025 that the US was in a "non-international armed conflict" with "unlawful combatants" regarding drug cartels in the Caribbean, specifically referencing the 15 September strike. The Miami Herald wrote that: "In an armed conflict, a country can lawfully kill enemy fighters even when they pose no threat." Initially positioned as a mission to stop narcotics traffic to the US, by mid-October, Venezuelan opposition figures and independent analysts stated the American objective had shifted to regime change, with Trump acknowledging the possibility of strikes within Venezuelan territory. On 16 October, Admiral Alvin Holsey, the commander of United States Southern Command, announced that he would retire at the end of the year, less than a year into what is normally a three-year placement, with anonymous sources reporting tension between Holsey and the Trump administration over Venezuela. Two unnamed officials told The Wall Street Journal that tension between Hegseth and Holsey began early during Trump's administration over military planning involving the Panama Canal, with Hegseth wanting to replace Holsey, but differences intensified when "Holsey was initially concerned about murky legal authority for the boat strike campaign" and "objected that parts of the operations fell outside his direct control". The sources stated that, after months of tension, there was a confrontational meeting in October, and Holsey's resignation was announced the same day.
=== Joint definition by IUPAP and IUPAC === The existence of two distinct units with the same name was confusing, and the difference (about 1.000282 in relative terms) was large enough to affect high-precision measurements. Moreover, it was discovered that the isotopes of oxygen had different natural abundances in water and in air. In April 1957 Alfred O. C. Nier suggested to Josef Mattauch that carbon-12 be adopted as the mass scale because of carbon's use as a secondary standard in mass spectrometry. Also, carbon-12 implied acceptable relative changes in the atomic weight scale, i.e., 42 parts-per-million (ppm) compared to 275 ppm for oxygen-16, which would not be acceptable to chemists. Following the approval of the International Union of Pure and Applied Physics (IUPAP) General Assembly at Ottawa, Canada, in 1960 and the International Union of Pure and Applied Chemistry (IUPAC) General Assembly at Montreal, Canada, in 1961, the atomic weights were officially given on the carbon-12 scale for the first time. The new unit was named the "unified atomic mass unit" and given a new symbol "u", to replace the old "amu" that had been used for the oxygen-based unit. However, the old symbol "amu" has sometimes been used after 1961 to refer to the new unit, particularly in lay and preparatory contexts. With this new definition, the standard atomic weight of carbon is about 12.011 Da and that of oxygen is about 15.999 Da. These values, generally used in chemistry, are based on averages of many samples from Earth's crust, its atmosphere, and organic materials.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.
The precursor, prothymosin alpha, is encoded by the PTMA gene in humans. The 28-residue peptide corresponds to the N-terminal segment released from that larger protein.
It is produced as a fragment of prothymosin alpha and is present in many tissues. Circulating concentrations are low, which makes routine measurement difficult.